Denali Therapeutics (NASDAQ:DNLI) Price Target Lowered to $87.00 at HC Wainwright

Denali Therapeutics (NASDAQ:DNLI) had its target price decreased by HC Wainwright from $90.00 to $87.00 in a research note issued to investors on Tuesday,Benzinga reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for Denali Therapeutics’ FY2026 earnings at ($0.58) EPS, FY2027 earnings at $1.82 EPS, FY2028 earnings at $4.16 EPS and FY2029 earnings at $6.29 EPS.

A number of other research firms have also recently commented on DNLI. Raymond James restated a “market perform” rating on shares of Denali Therapeutics in a research report on Thursday, October 10th. Cantor Fitzgerald lowered shares of Denali Therapeutics from an “overweight” rating to a “neutral” rating in a research note on Monday, October 7th. Jefferies Financial Group lifted their price objective on Denali Therapeutics from $40.00 to $45.00 and gave the stock a “buy” rating in a report on Friday, November 1st. William Blair assumed coverage on Denali Therapeutics in a research report on Friday, January 3rd. They issued an “outperform” rating on the stock. Finally, JPMorgan Chase & Co. lowered their price target on Denali Therapeutics from $29.00 to $28.00 and set an “overweight” rating on the stock in a research note on Friday, October 11th. Two research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $38.91.

Denali Therapeutics Trading Up 0.3 %

Denali Therapeutics stock opened at $21.25 on Tuesday. The firm has a market cap of $3.06 billion, a PE ratio of -7.70 and a beta of 1.39. The stock’s 50 day simple moving average is $24.23 and its two-hundred day simple moving average is $24.86. Denali Therapeutics has a 12 month low of $14.56 and a 12 month high of $33.33.

Denali Therapeutics (NASDAQ:DNLI) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($0.63) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.03). During the same period last year, the business posted ($0.72) EPS. On average, equities research analysts forecast that Denali Therapeutics will post -2.71 EPS for the current year.

Insider Transactions at Denali Therapeutics

In other Denali Therapeutics news, CEO Ryan J. Watts sold 40,000 shares of the business’s stock in a transaction that occurred on Friday, October 18th. The stock was sold at an average price of $27.69, for a total value of $1,107,600.00. Following the sale, the chief executive officer now owns 235,807 shares of the company’s stock, valued at $6,529,495.83. The trade was a 14.50 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Steve E. Krognes sold 3,339 shares of the company’s stock in a transaction on Tuesday, January 7th. The stock was sold at an average price of $20.81, for a total value of $69,484.59. Following the transaction, the director now owns 25,757 shares in the company, valued at $536,003.17. This trade represents a 11.48 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 104,518 shares of company stock worth $2,576,982 in the last quarter. Company insiders own 7.90% of the company’s stock.

Institutional Investors Weigh In On Denali Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the company. CWM LLC grew its stake in shares of Denali Therapeutics by 43.6% in the third quarter. CWM LLC now owns 2,153 shares of the company’s stock worth $63,000 after acquiring an additional 654 shares in the last quarter. Quest Partners LLC purchased a new position in Denali Therapeutics in the third quarter valued at $73,000. Assetmark Inc. grew its position in shares of Denali Therapeutics by 18.0% during the third quarter. Assetmark Inc. now owns 3,808 shares of the company’s stock worth $111,000 after buying an additional 580 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its holdings in Denali Therapeutics by 21.6% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,178 shares of the company’s stock worth $152,000 after acquiring an additional 920 shares in the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Denali Therapeutics in the 2nd quarter valued at approximately $194,000. Hedge funds and other institutional investors own 92.92% of the company’s stock.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.